IDXX

SEC source: 0001567619-21-011451 · doc1.xml · nonDerivative · entry 4

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 650,015

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $561.005 to a high of $561.92 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-21-011451 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 651,679

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $560.00 to a high of $561.00 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-21-011451 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 654,161

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-016515 · doc1.xml · nonDerivative · entry 1

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,866

F1 · balance_after: Amendment is being filed to correct the number of shares of Issuer common stock held.

SEC source: 0001567619-21-011201 · doc1.xml · derivative · entry 8

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 5,000 shares

Expires 2025-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy 74,316 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-21-011201 · doc1.xml · nonDerivative · entry 5

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 653,701

SEC source: 0001567619-21-011201 · doc1.xml · nonDerivative · entry 4

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 653,901

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $552.00 to a high of $552.675 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-21-011201 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 658,701

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-011202 · doc1.xml · nonDerivative · entry 2

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,866

SEC source: 0001567619-21-011202 · doc1.xml · nonDerivative · entry 1

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,866

SEC source: 0001567619-21-011201 · doc1.xml · derivative · entry 7

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 5,000 shares

Expires 2025-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy 74,316 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-21-011201 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 653,701

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $546.545 to a high of $547.27 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-21-011201 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 658,701

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-011069 · doc1.xml · derivative · entry 3

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,402

Underlying: Common Stock · 2,500 shares

Expires 2026-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the date of the 2017 annual meeting of shareholders.

SEC source: 0001567619-21-011069 · doc1.xml · nonDerivative · entry 2

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,886

SEC source: 0001567619-21-011069 · doc1.xml · nonDerivative · entry 1

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,386

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-011068 · doc1.xml · nonDerivative · entry 3

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,766

SEC source: 0001567619-21-011066 · doc1.xml · derivative · entry 6

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 5,000 shares

Expires 2025-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Not applicable.

F4 · derivative.exercise_date: Grant of option to buy 74,316 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-21-011066 · doc1.xml · nonDerivative · entry 4

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 653,701

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $538.10 to a high of $538.505 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-21-011066 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 654,116

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $537.09 to a high of $538.09 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-21-011066 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 656,174

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $536.00 to a high of $537.00 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-21-011066 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 658,701

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-011068 · doc1.xml · nonDerivative · entry 2

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,766

SEC source: 0001567619-21-011068 · doc1.xml · nonDerivative · entry 1

Turner Kathy V · CIK 0001740719 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,766

F1 · balance_after: Includes 12 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2021.

SEC source: 0001567619-21-010825 · doc1.xml · nonDerivative · entry 1

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,209

F1 · balance_after: Includes 12 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2021.

SEC source: 0001567619-21-010824 · doc1.xml · derivative · entry 4

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 7,632 shares

Expires 2025-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy 74,316 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-21-010824 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 653,701

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $528.00 to a high of $528.355 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-21-010824 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 661,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-010259 · doc1.xml · derivative · entry 2

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723

Underlying: Common Stock · 723 shares

Expires 2031-05-11

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010259 · doc1.xml · derivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224

Underlying: Common Stock · 224 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock on the vesting date.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock on the vesting date.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock on the vesting date.

SEC source: 0001567619-21-010257 · doc1.xml · derivative · entry 2

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723

Underlying: Common Stock · 723 shares

Expires 2031-05-11

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010257 · doc1.xml · derivative · entry 1

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224

Underlying: Common Stock · 224 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock on the vesting date.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock on the vesting date.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock on the vesting date.

SEC source: 0001567619-21-010256 · doc1.xml · derivative · entry 2

SAMAD SAM · CIK 0001694295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723

Underlying: Common Stock · 723 shares

Expires 2031-05-11

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010256 · doc1.xml · derivative · entry 1

SAMAD SAM · CIK 0001694295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 887

Underlying: Common Stock · 224 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001567619-21-010254 · doc1.xml · derivative · entry 2

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723

Underlying: Common Stock · 723 shares

Expires 2031-05-11

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010254 · doc1.xml · derivative · entry 1

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,387

Underlying: Common Stock · 224 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001567619-21-010255 · doc1.xml · derivative · entry 4

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 975

Underlying: Common Stock · 252 shares

Expires 2031-05-11

F2 · shares: Additional grant made pursuant to reporting person's role as Non-Executive Board Chair.

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010255 · doc1.xml · derivative · entry 3

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723

Underlying: Common Stock · 723 shares

Expires 2031-05-11

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010255 · doc1.xml · derivative · entry 2

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 302

Underlying: Common Stock · 78 shares

Expires not disclosed

F1 · derivative.exercise_price: \Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

F2 · shares: Additional grant made pursuant to reporting person's role as Non-Executive Board Chair.

F4 · price: Not applicable.

F1 · derivative.exercise_date: \Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

F1 · derivative.expiration_date: \Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010255 · doc1.xml · derivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224

Underlying: Common Stock · 224 shares

Expires not disclosed

F1 · derivative.exercise_price: \Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

F4 · price: Not applicable.

F1 · derivative.exercise_date: \Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

F1 · derivative.expiration_date: \Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010253 · doc1.xml · derivative · entry 2

ESSIG STUART · CIK 0001187574 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723

Underlying: Common Stock · 723 shares

Expires 2031-05-11

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010253 · doc1.xml · derivative · entry 1

ESSIG STUART · CIK 0001187574 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224

Underlying: Common Stock · 224 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010252 · doc1.xml · derivative · entry 2

COLLINS Asha · CIK 0001832272 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723

Underlying: Common Stock · 723 shares

Expires 2031-05-11

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010252 · doc1.xml · derivative · entry 1

COLLINS Asha · CIK 0001832272 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333

Underlying: Common Stock · 224 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001567619-21-010250 · doc1.xml · derivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723

Underlying: Common Stock · 723 shares

Expires 2031-05-11

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010250 · doc1.xml · derivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224

Underlying: Common Stock · 224 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010251 · doc1.xml · derivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723

Underlying: Common Stock · 723 shares

Expires 2031-05-11

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010251 · doc1.xml · derivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,552

Underlying: Common Stock · 224 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001567619-21-011451 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 644,701

SEC source: 0001567619-21-009749 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 653,701